TRPV1 modulator that does not cause hyperthermia in rats
暂无分享,去创建一个
J. Louis | B. H. Manning | N. Gavva | E. Magal | S. Lehto | N. Tamayo | L. Klionsky | Weiya Wang | J. Rubino | H. Deng | Rongzhen Kuang | Doo Lee | Tingrong Wang | Judy Wang | Jue Wang | Maosheng Zhang | R. Tamir | A. Le | D. Zhu | M. H. Norman
[1] Mark J. Rose,et al. Pharmacological blockade of the vanilloid receptor TRPV1 elicits marked hyperthermia in humans , 2008, PAIN.
[2] P. Chakrabarti,et al. Design and synthesis of peripherally restricted transient receptor potential vanilloid 1 (TRPV1) antagonists. , 2008, Journal of medicinal chemistry.
[3] J. Treanor,et al. Repeated Administration of Vanilloid Receptor TRPV1 Antagonists Attenuates Hyperthermia Elicited by TRPV1 Blockade , 2007, Journal of Pharmacology and Experimental Therapeutics.
[4] N. Chen,et al. Novel vanilloid receptor-1 antagonists: 2. Structure-activity relationships of 4-oxopyrimidines leading to the selection of a clinical candidate. , 2007, Journal of medicinal chemistry.
[5] J. Treanor,et al. Novel vanilloid receptor-1 antagonists: 3. The identification of a second-generation clinical candidate with improved physicochemical and pharmacokinetic properties. , 2007, Journal of medicinal chemistry.
[6] A. Szallasi,et al. The vanilloid receptor TRPV1: 10 years from channel cloning to antagonist proof-of-concept , 2007, Nature Reviews Drug Discovery.
[7] P. Blumberg,et al. Antinociceptive Pharmacology of N-(4-Chlorobenzyl)-N′-(4-hydroxy-3-iodo-5-methoxybenzyl) Thiourea, a High-Affinity Competitive Antagonist of the Transient Receptor Potential Vanilloid 1 Receptor , 2007, Journal of Pharmacology and Experimental Therapeutics.
[8] J. Treanor,et al. The Vanilloid Receptor TRPV1 Is Tonically Activated In Vivo and Involved in Body Temperature Regulation , 2007, The Journal of Neuroscience.
[9] N. Gavva,et al. The TRPV1 receptor and nociception. , 2006, Seminars in cell & developmental biology.
[10] Daniel J. Levitin,et al. Social Modulation of Pain as Evidence for Empathy in Mice , 2006, Science.
[11] E. Pintér,et al. Involvement of transient receptor potential vanilloid 1 in the vascular and hyperalgesic components of joint inflammation. , 2005, Arthritis & Rheumatism.
[12] A. Gomtsyan,et al. A-425619 [1-Isoquinolin-5-yl-3-(4-trifluoromethyl-benzyl)-urea], a Novel Transient Receptor Potential Type V1 Receptor Antagonist, Relieves Pathophysiological Pain Associated with Inflammation and Tissue Injury in Rats , 2005, Journal of Pharmacology and Experimental Therapeutics.
[13] Mark H. Norman,et al. AMG 9810 [(E)-3-(4-t-Butylphenyl)-N-(2,3-dihydrobenzo[b][1,4] dioxin-6-yl)acrylamide], a Novel Vanilloid Receptor 1 (TRPV1) Antagonist with Antihyperalgesic Properties , 2005, Journal of Pharmacology and Experimental Therapeutics.
[14] N. Carruthers,et al. Selective Blockade of the Capsaicin Receptor TRPV1 Attenuates Bone Cancer Pain , 2005, The Journal of Neuroscience.
[15] S. McMahon,et al. Acid-Induced Pain and Its Modulation in Humans , 2004, The Journal of Neuroscience.
[16] P. Anand,et al. Increased capsaicin receptor TRPV1 nerve fibres in the inflamed human oesophagus , 2004, European journal of gastroenterology & hepatology.
[17] J. Pomonis,et al. N-(4-Tertiarybutylphenyl)-4-(3-cholorphyridin-2-yl)tetrahydropyrazine -1(2H)-carbox-amide (BCTC), a Novel, Orally Effective Vanilloid Receptor 1 Antagonist with Analgesic Properties: II. In Vivo Characterization in Rat Models of Inflammatory and Neuropathic Pain , 2003, Journal of Pharmacology and Experimental Therapeutics.
[18] P. McIntyre,et al. The VR1 Antagonist Capsazepine Reverses Mechanical Hyperalgesia in Models of Inflammatory and Neuropathic Pain , 2003, Journal of Pharmacology and Experimental Therapeutics.
[19] S. Teague,et al. Functional Properties of the High-Affinity TRPV1 (VR1) Vanilloid Receptor Antagonist (4-Hydroxy-5-iodo-3-methoxyphenylacetate ester) Iodo-Resiniferatoxin , 2002, Journal of Pharmacology and Experimental Therapeutics.
[20] C. Woolf,et al. p38 MAPK Activation by NGF in Primary Sensory Neurons after Inflammation Increases TRPV1 Levels and Maintains Heat Hyperalgesia , 2002, Neuron.
[21] Vincent J. Dupriez,et al. Adaptation of Aequorin Functional Assay to High Throughput Screening , 2002, Journal of biomolecular screening.
[22] S. Bevan,et al. Pharmacological differences between the human and rat vanilloid receptor 1 (VR1) , 2001, British journal of pharmacology.
[23] S. Bingham,et al. Vanilloid receptor-1 is essential for inflammatory thermal hyperalgesia , 2000, Nature.
[24] A I Basbaum,et al. Impaired nociception and pain sensation in mice lacking the capsaicin receptor. , 2000, Science.
[25] P. Blumberg,et al. Vanilloid (Capsaicin) receptors and mechanisms. , 1999, Pharmacological reviews.